

Dr. Kian Kani Publications

1. Tiemann K, Garri C, Lee SG, Mallihi PD, Park M, Alvarez RM, Yap LP, Mallick P, Katz JE, Gross ME, Kani K. [Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis.](#) *Oncogene*. Dec 21. 2018. s41388-018-0638-9.
2. Juarez FJ, Garri GG, Gaffarizadeh A, Macklin P, Kani K. [Quantification of Cancer Cell Migration with an Integrated Experimental-Computational Pipeline.](#) *F100Research*. 2018.
3. Tiemann K, Garri GG, Wang J, Kani K. [Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays.](#) *Jove*. In Press 2018.
4. Hughes NP, Xu L, Nielsen NC, Chang E, Hori S, Natarajan A, Lee S, Kjær A, Kani K, Wang XS, Mallick PM, Gambhir S. [A Blood Biomarker for Monitoring Response to anti-EGFR Therapy.](#) *Cancer Biomarkers*. 2018;22(2):333-344.
5. Garri C, Howell S, Tiemann K, Tiffany A, Yazd T, Takaha T, Landgraf R, Gross ME, Roberts R, Kani K. [Identification, Characterization and Application of a New Peptide Against Anterior Gradient Homolog 2.](#) *Oncotarget*. 2018 Jun 8;9(44):27363-27379.
6. Poon C, Chowdhuri S, Kuo CH, Fang Y, Alenghat FJ, Hyatt D, Kani K, Gross ME, Chung EJ. [Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles.](#) *ACS Biomaterials Science & Engineering* 2017 3 (12), 3273-3282
7. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P. [JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines.](#) *Mol Cancer Ther*. 2017 May 31. pii: molcanther.0564.2016.
8. Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. [Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.](#) *Endocr Relat Cancer*. 2017 Apr;24(4):157-170. doi: 10.1530/ERC-16-0138. PubMed PMID: 28264911; PubMed Central PMCID: PMC5453797.
9. Kani K. [Quantitative Proteomics Using SILAC.](#) *Methods Mol Biol*. 2017;1550:171-184. doi: 10.1007/978-1-4939-6747-6\_13. PubMed PMID: 28188530.
10. Frieboes HB, Curtis LT, Wu M, Kani K, Mallick P. [Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor.](#) *Cancer Inform*. 2015 Dec 20;14:163-75. doi: 10.4137/CIN.S35374. eCollection 2015. PubMed PMID: 26715830; PubMed Central PMCID: PMC4687979.
11. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. [Anterior gradient 2 \(AGR2\): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.](#) *Prostate*. 2013 Feb 15;73(3):306-15. doi: 10.1002/pros.22569. Epub 2012 Aug 21. PubMed PMID: 22911164.
12. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P. [A cross-platform toolkit for mass spectrometry and proteomics.](#) *Nat Biotechnol*. 2012 Oct;30(10)
13. Zhang Q, Park E, Kani K, Landgraf R. [Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.](#) *Proc Natl Acad Sci U S A*

- A. 2012 Aug 14;109(33):13237-42. doi: 10.1073/pnas.1200105109. Epub 2012 Jun 25. PubMed PMID: 22733765; PubMed Central PMCID: PMC3421218.
14. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. [Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.](#) Mol Cancer Ther. 2012 May;11(5):1071-81. doi: 10.1158/1535-7163.MCT-11-0852. Epub 2012 Mar 12. PubMed PMID: 22411897; PubMed Central PMCID: PMC3959865.
  15. Kani K, Sordella R, Mallick P. [Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.](#) Methods Mol Biol. 2012;795:233-53. doi: 10.1007/978-1-61779-337-0\_16. PubMed PMID: 21960227.
  16. Vogelsang MS, Kani K, Katz JE, Mallick P. [Model-based discovery of circulating biomarkers.](#) Methods Mol Biol. 2011;728:87-107. doi: 10.1007/978-1-61779-068-3\_5. PubMed PMID: 21468942.
  17. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. [Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.](#) PLoS One. 2011;6(7):e23090. doi: 10.1371/journal.pone.0023090. Epub 2011 Jul 29. PubMed PMID: 21829587; PubMed Central PMCID: PMC3146523.
  18. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. [Precursor-ion mass re-estimation improves peptide identification on hybrid instruments.](#) J Proteome Res. 2008 Sep;7(9):4031-9. doi: 10.1021/pr800307m. Epub 2008 Aug 16. PubMed PMID: 18707148; PubMed Central PMCID: PMC4673049.
  19. Warren CM, Kani K, Landgraf R. [The N-terminal domains of neuregulin 1 confer signal attenuation.](#) J Biol Chem. 2006 Sep 15;281(37):27306-16. Epub 2006 Jul 6. PubMed PMID: 16825199.
  20. Kani K, Park E, Landgraf R. [The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.](#) Biochemistry. 2005 Dec 6;44(48):15842-57. PubMed PMID: 16313187.
  21. Kani K, Warren CM, Kaddis CS, Loo JA, Landgraf R. [Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.](#) J Biol Chem. 2005 Mar 4;280(9):8238-47. Epub 2004 Dec 20. PubMed PMID: 15611073.